CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER
Status:
Active, not recruiting
Trial end date:
2021-03-25
Target enrollment:
Participant gender:
Summary
A single-center, phase II, single-arm, feasibility study to evaluate PLD (Caelyx®) as an
adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer.
The primary endpoint will be to evaluate the feasibility of adjuvant PLD (Caelyx®) for each
individual subject. The regimen will be considered feasible if that subject is able to
achieve relative dose intensity (RDI) of at least 85% of the 8 cycles of treatment.
Caelyx® should be administered intravenously at a dose of 20 mg/m2 once every two weeks for 8
courses.